中
Home
About Us
About Haihe Biopharma
Mission and Vision
Management Team
Company Milestones
Awards
Research & Development
Strong, Innovation-driven R&D Capabilities
R&D Pipeline
Investor Partnerships & BD
Investors
Business Development
News Center
News
Interview
Career
Our Culture
Salary and Benefits
Employee
Job
中文
日本語
News Center
Press Release
2025.11.07
Haihe Biopharma's innovative drug PARP1 inhibitor has obtained clinical trial approval in China
Today, Haihe Biopharma (Haihe), announced that the companys self-developed selective PARP1 inhibitor (R&D code: HH10...
2025.10.16
Haihe Biopharma Enters Into Exclusive License Agreement with Taiho Pharma for PI3Kα Inhibitor Risovalisib (CYH33)
Haihe Biopharma Co., Ltd. (hereinafter “Haihe”) and Taiho Pharmaceutical Co., Ltd. (hereinafter “Taiho”) (“HaiHe”)...
Press Release
2019.08.27
First patient dosed in the Phase Ib clinical trial of Glumetinib by HaiHe Biopharma in the treatment of MET-positive advanced non-small cell lung cancer
2019.08.26
HaiHe Biopharma Cooperates with Junshi Biosciences to Explore the Combination of Glumetinib and Toripalimab
2019.08.19
HaiHe Biopharma Obtains a World-wide Exclusive License from Shanghai Institute of Materia Medica and Jinan University for a New Anti-Tumor Drug
2019.07.19
First subject recently dosed in the Phase II clinical trial of simmitecan LP-201 by HaiHe Biopharma in the treatment of neuroendocrine carcinoma
2019.05.01
HaiHe Biopharma’s Oral Paclitaxel RMX3001 has recently completed the first subject administration for the treatment of advanced gastric cancer phase III clinical trial
2019.03.05
HaiHe Biopharma Accomplished First Subject Enrollment of LP-X Pivotal Phase II Clinical Trial for Simmitecan
2019.02.11
HaiHe Biopharma Reached $146.6 Million Financing Agreement
2019.01.23
HaiHe Biopharma Accomplished First Subject Enrollment ofLucitanib AL3810-202 for Pivotal Phase IIb Clinical Trial for Thymic Cancer.
5
6
7
Interview
|
Legal statement
|
Disclaimers
|
Contact
|
Follow Us
©
2020 All Rights Reserved Haihe Biopharma Co., Ltd.
沪ICP备12016151号-1
.jpg)
